Low-dose thalidomide treatment for advanced hepatocellular carcinoma

Oncology

Volumn 65, Issue 3, 2003, Pages 242-249

  Hsu, Chiun ^a,b   Chen, Chiung Nien ^a   Chen, Li Tzong ^c,d   Wu, Chen Yao ^a   Yang, Pei Ming ^a   Lai, Ming Yang ^a,b   Lee, Po Huang ^a   Cheng, Ann Lii ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Thalidomide

Indexed keywords

ALPHA FETOPROTEIN; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HUMAN; INSOMNIA; LETHARGY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; AGED; ALPHA-FETOPROTEINS; ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0344305652     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074477     Document Type: Article

References (45)

1. Okuda K: Hepatocellular carcinoma. J Hepatol 2000;32(suppl 1):s225-s237.
2. Venook AP: Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 1994;12:1323-1334.
3. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-991.
4. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, Huang SM, Su IJ: Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: An immunohistochemical study. Hum Pathol 1997;28:698-703.
5. Chow NH, Cheng KS, Lin PW, Chan SH, Su WC, Sun YN, Lin XZ: Expression of fibroblast growth factor-1 and fibroblast growth factor-2 in normal liver and hepatocellular carcinoma. Dig Dis Sci 1998;10:2261-2266.
6. Harada T, Arii S, Mise M, Imamura T, Higashitsuji H, Furutani M, Niwano M, Ishigami S, Fukumoto M, Seiki M, Sato H, Imamura M: Membrane-type matrix metalloproteinase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 1998;28:231-239.
7. Ogata R, Torimura T, Kin M, Ueno T, Tateishi Y, Kuromatsu R, Shimauchi Y, Sakamoto M, Tamaki S, Sata M, Tanikawa K: Increased expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinomas. Hum Pathol 1999;30:443-450.
8. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, Nabika T, Nagasue N: Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-1562.
9. Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J: Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: A prospective study. Ann Surg 2001;233:227-235.
10. Somers GF: Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960;15:111-116.
11. McBride WG: Thalidomide and congenital abnormalities. Lancet 1961;ii:1358.
12. Marriott JB, Muller G, Dalgleish AG: Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999;20:538-540.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91: 4082-4085.
14. Kenyon BM, Browne F, D'Amato R: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978.
15. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571.
16. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yachoan R: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-2602.
17. Patt YZ, Hassan MM, Lozano RD, Zeldis JB, Schnirer I, Frome A, et al: Phase II trial of thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2000;18:1035.
18. Kong HL, Boyer MJ, Lim R, Clarke S, Millward MJ, Wong JE: Phase II trial of thalidomide in unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2001;19:2282.
19. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ: Alpha-fetoprotein changes in the course of chronic hepatitis: Relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6:133-137.
20. Okuda K: Early detection of hepatocellular carcinoma. Hepatology 1986;6:729-738.
21. American Joint Committee on Cancer: Manual for Staging of Cancer, ed 4. Philadelphia, Lippincott, 1992.
22. Okuda K: Early detection of hepatocellular carcinoma. Hepatology 1986;6:729-738.
23. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998;28:751-755.
24. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
25. Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0. National Cancer Institute. Available at URL: http://ctep.info.nih.gov
26. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, AhemR, Smith IE, Gore ME: Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812-817.
27. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2001;20:302-306.
28. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18:708-715.
29. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7:1888-1893.
30. The Cancer of the Liver Italian Program (CLIP) Investigators: Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31:841-845.
31. Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T: Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001;34:529-534.
32. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 2001;19:265-272.
33. Schilsky RL: End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935-938.
34. Eisen T: Thalidomide in solid malignancies. J Clin Oncol 2002;20:2607-2609.
35. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M: Characteristic difference of hepatocellular carcinoma between hepatitis Band C-viral infection in Japan. Hepatology 1995;22:1027-1033.
36. Hwang SJ, Tong MJ, Lai PP, Ko ES, Co RL, Chien D, Kuo G: Evaluation of hepatitis B and C viral markers: Clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol 1996;11:949-954.
37. Yamanaka N, Tanaka T, Tanaka W, Yamanaka J, Yasui C, Kuroda N, Takada M, Okamoto E: Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma. Cancer 1997;79:1509-1515.
38. Chen MF, Jeng LB, Lee WC, Chen TC: Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma. Surgery 1998;123:554-559.
39. Chen TH, Tseng LM, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Hsia CY, Wu CW: Clinicopathologic and prognostic differences between patients with hepatitis B- and C-related resectable hepatocellular carcinoma. J Formos Med Assoc 2001;100:443-448.
40. Mazzanti R, Messerini L, Monsacchi L, Buzzelli G, Zignego AL, Foschi M, Monti M, Laffi G, Mrbidelli L, Fantappie O, Bartoloni Saint Omer F, Ziche M: Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlated with increased liver angiogenesis. Hepatology 1997;25:229-234.
41. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayash IK: Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2000;120:955-966.
42. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S, Hamamoto Y: Comparison of gene expression profiles between hepatitis B virus-and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62:3939-3944.
43. Richardson P, Hideshima T, Anderson K: Thalidomide: Emerging role in cancer medicine. Annu Rev Med 2002;53:629-657.
44. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525-4530.
45. Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man HW, Schafer P, Govinda S, Muller GW, Stirling DI, Dalgliesh AG: A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins Cancer Res 2003;63:593-599.